A Real-World Study of Second-line Therapies Among Radioiodine-refractory Differentiated Thyroid Cancer (RAI-R DTC) Patients

Real-World Evidence of Second-line Systematic Therapy With BRAF V600E Mutation-guided Dabrafenib + Trametinib or Mutation-agnostic Multi-targeted Tyrosine Kinase Inhibitors (MKIs) in Radioiodine-refractory Differentiated Thyroid Cancer (RAI-R DTC)

This study aims to assess patient characteristics and treatment patterns of second-line systematic therapies, including BRAF V600E mutation-guided dabrafenib plus trametinib (D+T) and MKIs, among Chinese adult patients with RAI-R DTC. This is a non-interventional study using secondary data derived from a real-world Electronic Health Record (rEHR) database in China.

Inclusion criteria:

• Patients with a diagnosis of thyroid cancer.
• Patients with a pathological confirmation of differentiated thyroid cancer (DTC).
• Patients who initiated either MKI monotherapy (lenvatinib, sorafenib, anlotinib, donafenib, apatinib, sunitinib, cabozantinib, pralsetinib) or D+T combination therapy between January 1, 2019 and December 31, 2025 (or the data cutoff date).
• Patients with no curative-intent thyroid cancer surgery within 3 months after initiation of systematic therapy.

Exclusion criteria:

• Patients participating in a blinded interventional clinical trial, or any open-label observational study involving D+T or MKI, during the study period.

Other protocol-defined inclusion/exclusion criteria may apply.